Lipid metabolism in patients with hematologic cancers

Vladimirova S.G.; Tarasova L.N.

doi:https://doi.org/10.17116/terarkh2015883116-120

Close metadata

Recommended articles:

Prospects for Nagutskaya no. 26 mineral water in correction of carbohydrate and lipid metabolism in patients with insulin resistance. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2025;(4):20-28

Comprehensive assessment of students’ health based on the results of examinations at the health center. Russian Journal of Preventive Medicine. 2025;(12):76-82

Metabolic correction of systemic oxidative-toxic lesions in urgent abdominal surgery. Pirogov Russian Journal of Surgery. 2026;(3):63-70

Abstract:

It is considered that hypercholesterolemia is life-threatening and low cholesterol levels are a positive factor. However, taking into consideration the fact that cholesterol plays a key role in cell proliferation, it should be remembered that its low blood level may be linked to high cholesterol demands from neoplastic cells. The literature review analyzes the results of recent investigations of lipid metabolism in patients with hematologic cancers and their other types. All given investigations show a significant reduction in the serum levels of total cholesterol and high-density lipoproteins in patients with hematological disease at its onset. The data for other indicators of the lipid transport system are ambiguous. Such changes have been elucidated to be associated with the accumulation of cholesterol in the leukemia cells due to enhanced synthesis de novo, a more active absorption from circulation and blocked release of its surplus. If the disease runs a favorable course, lipid metabolic parameters become normalized and, in case of remission, correspond to those seen in healthy individuals. They continue to decline in patients with disease progression. This allows the consideration of cholesterol, its fractions, and apolipoproteins as biochemical prognostic markers in hematological cancer patients and as indicators for assessment of treatment results. In addition, there is evidence for the effect of chemotherapeutic agents on lipid metabolism. Recent attempts to elaborate new treatment strategies, by using the current knowledge on the role of lipid metabolism in cancers, are considered.

Keywords:

lipid metabolism

cholesterol

lipoproteins

hematological cancers

acute leukemias

Authors:

Vladimirova S.G.

Kirovskiĭ NII gematologii i perelivaniia krovi Federal'nogo mediko-biologicheskogo agentstva Rossii

Tarasova L.N.

Kirovskiĭ NII gematologii i perelivaniia krovi Federal'nogo mediko-biologicheskogo agentstva Rossii

Close metadata

References:

Titov V.N. Zhirnye kisloty, lipidy (transportnye formy zhirnykh kislot) i apolipoproteiny (lipidperenosyashchie makromolekuly) — edinaya funktsional'naya sistema. Klinicheskaya laboratornaya diagnostika. 2007;1:3-10.
Bezuglov V.V., Konovalov S.S. (red.). Lipidy i rak. Ocherki lipidologii onkologicheskogo protsessa. SPb.: Praim-EVROZNAK; 2009.
Titov V.N., Lisitsyn D.M. Zhirnye kisloty. Fizicheskaya khimiya, biologiya i meditsina. M.-Tver': Triada; 2006.
Gubareva A.E. Obmen lipidov. V kn.: Severin E.S. (red) Biokhimiya: uchebnik. M.: GEOTAR-MED; 2003.
Rao KN. The significance of the cholesterol biosynthetic pathway in cell growth and carcinogenesis (review). Anticancer Res. 1995;15(2):309-314.
Sassano A, Katsoulidis E, Antico G et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res. 2007;67(9):4524-4532.
Titov V.N., Krylin V.V., Shiryaeva Yu.K. Profilaktika ateroskleroza. Pozitsionnaya spetsifichnost' triglitseridov, lipazy krovi, osobye lipidy moloka, modifikatsiya zhirnykh kislot rastitel'nykh masel i zhivotnykh zhirov. Klinicheskaya laboratornayadiagnostika. 2011;3:3-13.
Houston MC, Fazio S, Chilton FH et al. Nonpharmacologic treatment of dyslipidemia. Prog Cardiovasc Dis. 2009;52(2):61-94.
Titov V.N. Ateroskleroz kak patologiya polienovykh zhirnykh kislot. Biologicheskie osnovy teorii aterogeneza. M.: Fond «Klinika XXI veka»; 2002.
Moschovi M, Trimis G, Apostolakou F et al. Serum lipid alterations in acute lymphoblastic leukemia of childhood. J Pediatr HematolOncol. 2004;26(5):289-293.
Casalou C, Costa A, Carvalho T et al. Cholesterol Regulates VEGFR-1 (FLT-1) Expression and Signaling in Acute Leukemia Cells. Mol Cancer Res. 2011;9(2):215-224.
Pillozzi S, Brizzi MF, Bernabei PA et al. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood. 2007;110(4):1238-1250.
Qadir MI, Malik SA. Plasma lipid profile in gynecologic cancers. Eur J Gynaecol Oncol. 2008;29(2):158-161.
Kuliszkiewicz-Janus M, Małecki R, Mohamed AS. Lipid changes occuring in the course of hematological cancers. Cell Mol Biol Lett. 2008;13(3):465-474.
Cvetkovic Z, Cvetkovic B, Petrovic M et al. Lipid profile as a prognostic factor in cancer patients. J BUON. 2009;14(3):501-506.
Musolino C, Calabrò L, Bellomo G et al. Lipid profile in hematologic neoplasms. Recenti Prog Med. 2002;93(5):298-301.
Zalewska-Szewczyk B, Matusiak I, Wyka K et al. Changes in the lipid profile in children with acute lymphoblastic leukaemia — the influence of the disease and its treatment. Med Wieku Rozwoj. 2008;12(4 Pt 2):1035-1040.
Pugliese L, Bernardini I, Pacifico N et al. Severe hypocholesterolaemia is often neglected in haematological malignancies. Eur J Cancer. 2010;46(9):1735-1743.
Gonçalves RP, Rodrigues DG, Maranhão RC. Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leuk Res. 2005;29(8):955-959.
Freeman MR, Solomon KR. Cholesterol and prostate cancer. J CellBiochem. 2004;91(1):54-69.
Nygren C, von Holst H, Månsson JE, Fredman P. Increased levels of cholesterol esters in glioma tissue and surrounding areas of human brain. Br J Neurosurg. 1997;11(3):216-220.
Vitols S, Norgren S, Juliusson G et al. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood. 1994;84(8):2689-2698.
Tatidis L, Masquelier M, Vitols S. Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. BiochemPharmacol. 2002;63(12):2169-2180.
Steinherz PG. Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. Cancer. 1994;74(12):3234-3239.
Nakagawa M, Kimura S, Fujimoto K et al. A case report of an adult with severe hyperlipidemia during acute lymphocytic leukemia induction therapy successfully treated with plasmapheresis. TherApher Dial. 2008;12(6):509-513.
Seah J, Lin K, Tai D et al. Conservative management of L-asparaginase-induced hypertriglyceridemia in an adult patient: a case report and review of the literature. Onkologie. 2012;35(10): 596-598.
Lashkari HP, Lancaster D, Atra A et al. Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe? Int J Hematol. 2011;94(6):571-575.
Nesheli HM, Tamaddoni A, Nesheli MM et al. L-asparaginase induced hyperlipidaemia in acute lymphoblastic leukaemia. J PakMed Assoc. 2013;63(3):324-326.
Cohen H, Bielorai B, Harats D et al. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;54(5): 703-706.
Annaloro C, Airaghi L, Saporiti G et al. Metabolic syndrome in patients with hematological diseases. Expert Rev Hematol. 2012;5(4): 439-458.
Joukhadar R, Chiu K. Severe hypercholesterolemia in patients with graft-vs-host disease affecting the liver after stem cell transplantation. Endocr Pract. 2012;18(1):90-97.
Li HY, Appelbaum FR, Willman CL et al. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood. 2003;101(9):3628-3634.
Sassano A, Lo Iacono M, Antico G et al. Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins. Mol Cancer Ther. 2009;8(3):615-625.
Sassano A, Altman JK, Gordon LI, Platanias LC. Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation. Leuk Lymphoma. 2012;53(9):1779-1784.
Banker DE, Mayer SJ, Li HY et al. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood. 2004;104(6):1816-1824.
van der Weide K, de Jonge-Peeters S, Huls G et al. Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients. Exp Hematol. 2012;40(3): 177-186.
Titov V.N., Krylin V.V., Shiryaeva Yu.K. Profilaktika ateroskleroza. Izbytok v pishche pal'mitinovoi kisloty — prichina giperkholesterinemii, sindroma vospaleniya, rezistentnosti miotsitov k insulinu i apoptoza. Klinicheskaya laboratornayadiagnostika. 2011;2:4-15.
Yao X., Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer Causes Control. 2015; 26(2):257-268.
Allott EH, Howard LE, Cooperberg MR et al. Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014;23(11): 2349-2356.
Everatt R, Virvičiūtė D, Kuzmickienė I, Tamošiūnas A. Body mass index, cholesterol level and risk of lung cancer in Lithuanian men. Lung Cancer. 2014;85(3):361-365.
Nelson E.R, Chang CY, McDonnell DP. Cholesterol and breast cancer pathophysiology. Trends Endocrinol Metab. 2014;25(12): 649-655.
Rossi RE, Pericleous M, Mandair D et al. The Role of Dietary Factors in Prevention and Progression of Breast Cancer. AnticancerRes. 2014;34(12):6861-6875.
Berrino F, Villarini A, Traina A et al. Metabolic syndrome and breast cancer prognosis. Breast Cancer Res Treat. 2014;147(1): 159-165.
McDonnell DP, Chang CY, Nelson ER. The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer. Climacteric. 2014;17(Suppl 2):60-65.
McDonnell DP, Park S, Goulet MT et al. Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res. 2014;74(18):4976-4982.
Nagel G, Stocks T, Späth D et al. Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Ann Hematol. 2012;91(10):1519-1531.